Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin in type 2 diabetes mellitus with ischemic heart disease
2017-003779-75Phase 4Active
- Sponsor
- Hospital Universitario La Paz
- Start
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of empagliflozin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Hospital Universitario La Paz. Primary endpoint: Inflammatory activity. Started Oct 2017; status: active.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2017-003779-75.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003779-75.